# Research Pulse — 2026-08-20 _Generated 2026-08-20 07:30 KST · AI × Bioresearch Daily synthesis_ Brown Biotech daily research pulse — multi-front synthesis across CRISPR / gene editing, AI drug discovery, protein AI, single-cell foundation models, FDA/regulatory, and spatial transcriptomics. Sources: company filings, peer-reviewed journals, FDA guidance, conference disclosures. --- ### Post 1: 오늘의 전체 흐름 🧬 **AI × Bioresearch Daily — 8월 20일 (목요일) · Expanding(확산 Day)** 8/20(확산) → 8/19(Diversifying) → 8/18(Converging) → 8/17(Standardizing) → 8/16(Industrializing) → 8/15(Sustaining) → 8/14(Accelerating) → 8/13(Catalyzing) → ... → 7/14(가속). Diversifying(8/19)된 기술들이 **跨영역(cross-domain)으로 확산(Expanding)하여 새 적용 영역의 조건을 충족하는 날** — In situ sequencing(ISS)으로 CRISPR gene editing 공간적 profiling이 mice·macaques·종양/대사성 간 질환으로 확산(Janjuha Nature Biomedical Engineering 2025), de-targeting elements framework로 mRNA/LNP vaccine tissue competency mapping 가능성 확인(Froechlich Molecular Therapy 2026), RNA-LNP-mediated prime editing이 citrullinemia type 1(CTLN1) 치료 가능성으로 확산(Tálas Science Translational Medicine 2026), DrugCLIP contrastive learning으로 genome-wide virtual screening ultrafast 적용 가능성 확인(Zhang Drug Development Research 2026), big data healthcare framework가 4Vs → veracity·validity·viability 확장(Raghupathi Health Information Science Systems 2026), CAF-T cell purinergic axis adenosine signaling으로 NSCLC 예후 예측 biomarker 확립(Koppensteiner Oncoimmunology 2026), CD3+ B cells이 DLBCL tumor microenvironment 재구성으로 immunotherapy resistance mechanism 확산(Lang Cancer Biology Therapy 2026), CAPItello-281 FDA 승인으로 PTEN-deficient prostate cancer biomarker-guided targeted therapy paradigm 확립(Staton Cancer Biology Therapy 2026)이 동시에 진행된다. Expanding은 Diversifying의 다음 단계다. 오늘 6개 전선은 분기화된 기술들이 **跨영역 적용으로 새 영역의 조건을 충족하는 날**이다. *출처: [Janjuha ISS Spatial Profiling Nature Biomedical Engineering 2025](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/), [Froechlich mRNA LNP De-targeting Molecular Therapy 2026](https://consensus.app/papers/details/10.1016/j.ymthe.2026.07.050/), [Tálas CTLN1 Prime Editing Science Translational Medicine 2026](https://consensus.app/papers/details/10.1126/scitranslmed.aec7274/), [Zhang DrugCLIP Drug Development Research 2026](https://consensus.app/papers/details/10.1002/ddr.70351/), [Raghupathi Big Data Healthcare Health Information Science Systems 2026](https://consensus.app/papers/details/10.1007/s13755-026-00433-2/), [Koppensteiner CAF NSCLC Oncoimmunology 2026](https://consensus.app/papers/details/10.1080/2162402X.2026.2709221/)* *#ExpandingDay #ISS #InSituSequencing #SpatialProfiling #Janjuha #NatureBiomedicalEngineering #Froechlich #MolecularTherapy #DeTargeting #Tálas #ScienceTranslationalMedicine #CTLN1 #PrimeEditing #Zhang #DrugCLIP #ContrastiveLearning #VirtualScreening #Raghupathi #BigData #AIHealthcare #Koppensteiner #Oncoimmunology #NSCLC #Adenosine #CAF #Expanding #Diversifying #CrossDomain #SpatialGenomics #GeneEditing #Vaccine #TissueCompetency* --- ### Post 2: CRISPR & Gene Editing — In Situ Sequencing Spatial Profiling 확산과 mRNA/LNP Vaccine De-targeting 🧪 **[CRISPR/Gene Editing] In situ sequencing(ISS)으로 gene editing spatial profiling이 mice·macaques·종양/대사성 간 질환으로 확산(Janjuha Nature Biomedical Engineering 2025) + De-targeting elements framework로 mRNA/LNP vaccine tissue competency mapping + Cas9 de-immunization 가능성 확인(Froechlich Molecular Therapy 2026) + RNA-LNP-mediated PE7이 citrullinemia type 1 치료 가능성 확인(Tálas Science Translational Medicine 2026): CRISPR 기술의跨영역 확산(Expanding) 동시 확인** CRISPR 유전자 편집 기술의**跨영역 확산**이 출처에서 동시에 확인된다[1][2][3]. **In Situ Sequencing(ISS): Gene Editing Spatial Profiling의跨영역 확산[1]** Sharan Janjuha et al.(Nature Biomedical Engineering 2025)의 연구는 imaging-based in situ sequencing(ISS)으로 gene editing events를 공간적 분해능으로 매핑하는 기술을 제시한다. **기술 검증**: intein-split adenine base editors 또는 prime editors를 AAV vectors로 뇌에 전달한 마우스 모델에서 검증. **공간적 분해능**: in situ sequencing으로 gene editing events를 조직 내에서 직접 시각화. **Liver metabolic zones 적용**: RNA-LNP로 전달된 adenine base editor가 간의 모든 metabolic zones(lobule 전체)에서 유효한 editing 확인. **반복 투여 영향 없음**: 초기 용량이 subsequent dose의 editing efficiency와 분포에 영향 없음 확인. **Macaques 적용**: 비인간영장류에서도 spatial profiling 확장 가능성 확인. 핵심: ISS 기반 gene editing spatial profiling이 종양·대사성 간 질환으로 확산 — 유전자 편집의跨영역 적용. **mRNA/LNP Vaccine De-targeting: Tissue Competency Mapping + Cas9 De-immunization[2]** Guendalina Froechlich et al.(Molecular Therapy 2026)의 연구는 mRNA/LNP vaccine의 조직 특이적 면역 반응을 분석한다. **mRNA/LNP Vaccine의 문제**: biodistribution과 tissue-specific translation의 상관관계 불명확. **De-targeting elements framework**: 3' UTR에 microRNA target sites를 삽입하여 조직 특이적 antigen expression 억제 가능. **Immunologically competent tissues 동정**: muscle과 spleen이 robust immune priming에 필수적. **CRISPR-Cas9 적용 확장**: immune-active tissues에서 mRNA-Cas9 expression을 방지하여 immunogenicity와 toxicity 감소. 핵심: De-targeting elements로 vaccine optimization + Cas9 de-immunization 동시 달성 — vaccine-competent tissue mapping 체계 확산. **RNA-LNP PE7이 Citrullinemia Type 1 치료 가능성 확인[3]** András Tálas et al.(Science Translational Medicine 2026)의 연구는 PE7 prime editor의 CTLN1 치료 잠재력을 분석한다. **AAV 전달**: neonate에서 71%, juvenile에서 54% 교정율 달성. **RNA-LNP 전달**: neonate에서 24%(3mg/kg 1회), juvenile에서 13%(4mg/kg 3회) 교정율. **완전한 생존률 회복**: 혈중 citrulline과 ammonia 농도 정상화, 자연행동 결함 교정 확인. **간 제한적 editing**: indel formation 최소, off-target activity 최소, 일시적 간효소 상승만 관찰. 핵심: RNA-LNP-mediated prime editing으로 CTLN1 치료 가능성 확인 — 유전성 대사 질환으로 확산. **8월 19일 Diversifying Day vs 오늘의 차별점**: 8/19가 **Jiang Nature Nanotechnology**으로 **PE-LNP 49% in vivo prime editing + 반복 투여 가능성**을, **Wang Advanced Materials**으로 **PIL Dab4 LNP 설계 원리(SM-102 대비 우위)**를, **Rothgangl Nature Biomedical Engineering**으로 **PE7 20.7% 유전체 교정율(혈중 Phe 1,500→360 µmol/l)**을 제시했다면, 오늘은 **Janjuha Nature Biomedical Engineering**으로 **ISS로 gene editing spatial profiling을跨영역(mice·macaques·종양/대사성)으로 확산**을(공간적 적용), **Froechlich Molecular Therapy**으로 **mRNA/LNP vaccine optimization이 vaccine-competent tissue mapping으로 확산**을(vaccine에서 gene therapy로), **Tálas Science Translational Medicine**으로 **RNA-LNP PE7로 CTLN1 치료 가능성(AAV 71%/RNA-LNP 24% 교정율)**을(대사성 질환 적용) 동시에 제시한다. Diversifying(8/19) → 跨영역 적용 확산 Expanding(8/20). 실무 함의: 유전자 치료 전달 기술팀에서 Janjuha et al.의 ISS spatial profiling 접근법을 분석하여跨영역 적용 전략을 수립해야 한다. *출처: [Janjuha Spatial Profiling ISS Nature Biomedical Engineering 2025](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/), [Froechlich mRNA LNP De-targeting Molecular Therapy 2026](https://consensus.app/papers/details/10.1016/j.ymthe.2026.07.050/), [Tálas CTLN1 Prime Editing Science Translational Medicine 2026](https://consensus.app/papers/details/10.1126/scitranslmed.aec7274/)* *#CRISPR #GeneEditing #Janjuha #NatureBiomedicalEngineering #ISS #InSituSequencing #SpatialProfiling #Froechlich #MolecularTherapy #DeTargeting #MicroRNA #Vaccine #Tálas #ScienceTranslationalMedicine #CTLN1 #PrimeEditing #PE7 #RNA-LNP #ExpandingDay #CrossDomain #DeImmunization #TissueCompetency #Macaques #MetabolicZones #InVivoEditing #LiverDisease #MetabolicDisorder* --- ### Post 3: AI 신약 — DrugCLIP Contrastive Learning과 Big Data Healthcare Veracity Framework 확산 💊 **[AI 신약] DrugCLIP contrastive learning으로 ultrafast genome-wide virtual screening 가능성 확인(Zhang Drug Development Research 2026) + Big data healthcare framework가 4Vs → veracity·validity·viability로 확장 확인(Raghupathi Health Information Science Systems 2026) + AlphaFold structures의 antibiotic resistance therapeutic target discovery 적용 확산 확인(de Oliveira Teixeira Journal Computer-Aided Molecular Design 2026): AI drug discovery의跨영역 확산 동시 확인** AI-Driven Drug Discovery의**跨영역 확산**이 출처에서 동시에 확인된다[4][5][6]. **DrugCLIP: Contrastive Learning Ultrafast Genome-Wide Virtual Screening[4]** Jinwei Zhang(Drug Development Research 2026)의 commentary는 DrugCLIP의 contrastive learning 기반 virtual screening을 분석한다. **전통 virtual screening의 한계**: computational cost 높음, cross-target generalization 제한. **DrugCLIP의 혁신**: contrastive framework로 protein pocket과 small-molecule representations을 정렬. **GenPack**: predicted structures를 위한 targeted pocket refinement. **Benchmark 결과**: molecular docking과 machine learning baselines 대비 competitive performance 확인. **적용 사례**: psychiatric targets + cancer-associated targets에서 wet-lab success stories. **GenomeScreenDB resource**: resulting screening outcomes의 database 확립. **RosettaVS, Deep Docking, AF2-RAVE와 비교**: contemporary computational tools와의 상대적 위치 확립. 핵심: DrugCLIP contrastive learning으로 genome-wide virtual screening ultrafast 적용 확산 — AI-driven drug discovery의跨영역 적용. **Big Data Healthcare: 4Vs Framework 확장(Veracity·Validity·Viability)[5]** Wullianallur Raghupathi & Viju Raghupathi(Health Information Science Systems 2026)의 review는 10년 만에 big data in healthcare framework를 전면 개정한다. **배경**: Hadoop → cloud computing + GPU-accelerated AI로 transformation. **Landmark 변화**: AlphaFold의 Nobel Prize-winning protein structure prediction, FDA-cleared AI medical devices가 2015년 <10개 → mid-2025년 1,200개 이상. **4Vs 확장**: (1) Volume·Velocity·Variety 기존 + (2) Veracity → explainability 통해, (3) Validity → fairness 통해, (4) Viability → sustainability 통해. **Precision oncology·drug discovery·public health surveillance**에서의 breakthrough applications 확인. **새로운 도전**: algorithmic bias, opacity, environmental sustainability, privacy/security/data ownership/interoperability. 핵심: Big data healthcare framework가 4Vs → veracity/validity/viability로 확장 — AI healthcare의跨영역 적용 체계. **AlphaFold Structures의 Antimicrobial Resistance Therapeutic Target Discovery 적용[6]** Thayssa de Oliveira Teixeira et al.(Journal Computer-Aided Molecular Design 2026)의 review는 AI-driven structural modeling의 antimicrobial resistance 적용을 분석한다. **도전 과제**: antimicrobial resistance가 글로벌 공중보건 위협으로 지속 적화. **AlphaFold·RoseTTAFold의 역할**: multidrug-resistant bacterial genomes의 단백질 3D 구조 high-accuracy prediction으로 hypothetical proteins annotation과 conserved domains/catalytic sites 식별. **Computational approaches의 가치**: genomic data와 biological function 사이의 격차 해소. **적용**: drug discovery 가속화 + new antimicrobial bioactive compounds 설계 guidance. **현재 도전**: experimental validation 필요 + genomic variability 문제. 핵심: AlphaFold predicted structures가 antibiotic resistance therapeutic target discovery로 확산 — protein AI의跨영역 적용. **8월 19일 Diversifying Day vs 오늘의 차별점**: 8/19가 **Cai Pharmaceuticals**으로 **preclinical drug discovery 이행 장벽 체계적 분석**을, **Niazi Therapeutic Innovation**으로 **AI drug discovery 임상 진입 0건 현실**을 제시했다면, 오늘은 **Zhang Drug Development Research**으로 **DrugCLIP contrastive learning으로 genome-wide screening ultrafast 적용**을(새 적용 방식), **Raghupathi Health Information Science Systems**으로 **4Vs framework의 veracity·validity·viability로 확장**을(framework 확산), **de Oliveira Teixeira Journal Computer-Aided Molecular Design**으로 **AlphaFold structures가 antibiotic resistance로 확산**을(단백질 AI跨영역 적용) 동시에 제시한다. Diversifying(8/19) → AI drug discovery跨영역 적용 확산 Expanding(8/20). 실무 함의: AI drug discovery 협업팀에서 Zhang et al.의 DrugCLIP 접근법을 분석하여 ultrafast screening strategy를 수립해야 한다. *출처: [Zhang DrugCLIP Contrastive Learning Drug Development Research 2026](https://consensus.app/papers/details/10.1002/ddr.70351/), [Raghupathi Big Data Healthcare Health Information Science Systems 2026](https://consensus.app/papers/details/10.1007/s13755-026-00433-2/), [de Oliveira Teixeira AlphaFold AMR Journal Computer-Aided Molecular Design 2026](https://consensus.app/papers/details/10.1007/s10822-026-00905-3/)* *#AI #DrugDiscovery #Zhang #DrugCLIP #ContrastiveLearning #VirtualScreening #GenomeScreenDB #Raghupathi #BigData #Healthcare #Veracity #Validity #Viability #AlphaFold #deOliveiraTeixeira #AMR #AntimicrobialResistance #ExpandingDay #ProteinStructure #RoseTTAFold #TargetDiscovery #ComputationalBiology #DrugDesign #CrossDomain* --- ### Post 4: 단백질 AI — AlphaFold Drug Discovery 적용 확산과 GPR18 Neuroinflammatory Disorders 적용 🔬 **[단백질 AI] AlphaFold structures가 antibiotic resistance therapeutic target discovery로 확산 확인(de Oliveira Teixeira Journal Computer-Aided Molecular Design 2026) + GPR18 AlphaFold-based structural modeling으로 neuroinflammatory disorders 치료 표적 확인(Tortolani Biochemical Pharmacology 2026) + Dhir AI computational drug design workflow 종합(Dhir RSC Advances 2026): 단백질 AI의跨영역 적용 확산 동시 확인** 단백질 AI의**跨영역 적용 확산**이 출처에서 동시에 확인된다[7][8][9]. **AlphaFold Structures의 Antimicrobial Resistance Therapeutic Target Discovery 적용[7]** Thayssa de Oliveira Teixeira et al.(Journal Computer-Aided Molecular Design 2026)의 review는 AlphaFold·RoseTTAFold의 antibiotic resistance 적용을 분석한다. **Multidrug-resistant bacterial genomes**: 3D 구조 prediction으로 previously hypothetical proteins annotation 가능. **Conserved domains과 catalytic sites 식별**: drug targets discovery 가속화. **Computational approaches**: genomic-function gap 해소. **향후 방향**: experimental validation integration + AI-driven modeling과 bioinformatics 결합. 핵심: AlphaFold structures가 antimicrobial resistance therapeutic target discovery로 확산 — 단백질 AI跨영역 적용. **GPR18 Neuroinflammatory Disorders: AlphaFold Structural Modeling 치료 표적 확립[8]** Daniel Tortolani et al.(Biochemical Pharmacology 2026)의 review는 GPR18의 구조적 모델링과 치료 잠재력을 분석한다. **GPR18의 특성**: class A GPCR로 orphan receptor로 간주되었으나, extended endocannabinoid system의 pharmacologically relevant component로 재정의. **AlphaFold predicted structures 활용**: previously published homology models와 비교하여 conserved motifs, constitutive activity determinants, ligand-binding pocket의 동적 구조 분석. **Neuroinflammation에서의 역할**: microglia responses, neuroprotective mechanisms, resolvation pathways와 관련. **TREM2 signaling, NLRP3 inflammasome activation, complement cascade dysregulation**: 가장 임상적으로 실행 가능한 target들. **PLATO-based target fishing**: dual GPR18/CBR modulators 설계 전략. 핵심: GPR18 AlphaFold 기반 structural modeling으로 neuroinflammatory disorders 치료 표적 확립 — 단백질 AI의 신경 영역 적용. **AI Computational Drug Design Workflow: 포괄적 종합[9]** Ryena Dhir et al.(RSC Advances 2026)의 review는 AI-based drug discovery computational tools의 포괄적 workflow를 분석한다. **AI-based platforms의 transformation**: narrow focus → comprehensive platform으로. **Target identification**: graph-based drug-target interaction models. **Deep-learning docking**: GNINA, AtomNet. **Molecular generation**: REINVENT, RANC. **Multi-task ADMET prediction**: ADMETlab 2.0. **AlphaFold의 파급**: 200 million protein structures prediction으로 drug targets pool 확장. **Challenges**: dataset bias, reproducibility, real-world applicability. 핵심: AI computational drug design workflow 포괄적 종합 — drug discovery pipeline의全단계 AI 적용. **8월 19일 Diversifying Day vs 오늘의 차별점**: 8/19가 **Niazi Scientific Reports**으로 **FiveFold ensemble로 IDP·allosteric 분기화 적용**을, **Feldman Computational Biotechnology**으로 **AlphaFold mutation invariance 문제**를, **Nussinov Trends Pharmacological Sciences**으로 **conformational ensembles의 allosteric drug discovery**를 제시했다면, 오늘은 **de Oliveira Teixeira Journal Computer-Aided Molecular Design**으로 **AlphaFold structures가 antibiotic resistance로 확산**을(새 영역), **Tortolani Biochemical Pharmacology**으로 **GPR18 AlphaFold modeling으로 neuroinflammatory disorders 치료 표적**을(신경 영역), **Dhir RSC Advances**으로 **AI drug design workflow 全단계 포괄적 종합**을(파이프라인 통합) 동시에 제시한다. Diversifying(8/19) → 단백질 AI跨영역 적용 확산 Expanding(8/20). 실무 함의: 전산단백질 설계팀에서 Tortolani et al.의 GPR18 modeling 결과를 분석하여 neuroinflammatory disorders targeting strategy를 수립해야 한다. *출처: [de Oliveira Teixeira AlphaFold AMR Journal Computer-Aided Molecular Design 2026](https://consensus.app/papers/details/10.1007/s10822-026-00905-3/), [Tortolani GPR18 Biochemical Pharmacology 2026](https://consensus.app/papers/details/10.1016/j.bcp.2026.118038/), [Dhir AI Drug Design RSC Advances 2026](https://consensus.app/papers/details/10.1039/d6ra02374f/)* *#ProteinAI #AlphaFold #deOliveiraTeixeira #JournalComputerAidedMolecularDesign #AMR #AntimicrobialResistance #Tortolani #GPR18 #BiochemicalPharmacology #Neuroinflammation #Microglia #Dhir #RSCAdvances #AIDrugDesign #ComputationalWorkflow #ExpandingDay #CrossDomain #DrugDiscovery #ProteinStructure #RoseTTAFold #Neurodegenerative #TargetDiscovery #StructuralModeling* --- ### Post 5: Single-Cell Multi-Omics Foundation Model — Perturbation Prediction Adversarial Validation과 Conditional Flow Matching 확산 🬬 **[Single-Cell Multi-Omics Foundation Model] Foundation model perturbation prediction의 adversarial validation framework 확립으로 cross-domain 적용 검증(Kendiukhov Computational Biology Chemistry 2026) + CFM-GP conditional flow matching으로 gene perturbation across cell types 예측 확산(Abir NAR Genomics Bioinformatics 2026) + scYeast biological-knowledge-guided foundation model로 yeast systems biology 적용 확산(Fan Synthetic Systems Biotechnology 2026): foundation model의跨영역 적용 확산 동시 확인** Single-Cell Foundation Model의**跨영역 적용 확산**이 출처에서 동시에 확인된다[10][11][12]. **Foundation Model Perturbation Prediction: Adversarial Validation Framework 확립[10]** Ihor Kendiukhov et al.(Computational Biology and Chemistry 2026)의 연구는 Geneformer 기반 in silico gene-deletion perturbations에 대한 adversarial validation framework를 제시한다. **방법**: 21개 intelligence-linked genes에 대해 human dorsolateral prefrontal cortex(DLPFC) single-cell RNA-seq 데이터로 검증. **발견**: expression-matched empirical null testing 결과, 21개 유전자 perturbation effects 모두 FDR-significant 미도달(0/21). **Gene-set-level signal**: modest collective signal(Wilcoxon p=0.051)으로 suggestive 하지만 not confirmatory. **Combinatorial super-additivity**: directionally consistent하나 statistically fragile. **Cross-model concordance with scGPT**: tokenization incompatibilities로 limited(6/21 overlapping genes, ρ=0.66). **핵심 문제**: expression-level confounding이 raw perturbation signals을 substantially inflate. **권장**: expression-matched nulls를 minimum standard로 적용. 핵심: Foundation model perturbation prediction의 adversarial validation framework 확립 — cross-domain 적용 검증 체계. **CFM-GP: Conditional Flow Matching for Gene Perturbation Across Cell Types[11]** Abrar Rahman Abir et al.(NAR Genomics and Bioinformatics 2026)의 연구는 CFM-GP conditional flow matching framework를 제시한다. **문제**: gene perturbations가 세포 상태를 reshaping하는 mechanism를 모든 perturbation-cell type 조합에서 실험적으로 profiling하기 infeasible. **CFM-GP의 혁신**: control expression profiles를 perturbed states로 변환하는 continuous vector field를 학습. **Conditioning on cell type**: unified architecture로 common regulatory programs과 type-specific responses를 모두 모델링. **5개 single-cell perturbation datasets에서 검증**: predictive accuracy, distributional alignment, cross-species generalization 모두 superior. **Mechanistic interpretability**: inferred flow trajectories가 canonical signaling pathways와 context-dependent transcriptional cascades 회복. 핵심: CFM-GP conditional flow matching으로 gene perturbation prediction이跨세포종 적용으로 확산 — foundation model의 예측 정확도 향상. **scYeast: Biological-Knowledge-Guided Yeast Foundation Model[12]** Xingcun Fan et al.(Synthetic Systems Biotechnology 2026)의 연구는 scYeast foundation model을 제시한다. **주요 한계 극복**: 기존 large-scale pretrained models가 human/mouse에 집중 + biological prior knowledge 활용 부족. **scYeast 혁신**: transcriptional regulatory information를 Transformer's attention mechanism에 infusion하는 asymmetric parallel architecture. **Biological prior integration**: biology-guided training으로 강화. **다양한 downstream tasks**: cell state classification, growth doubling time prediction, gene perturbation response prediction. **Transfer learning**: proteomics으로 adaptation 가능. **Zero-shot tasks**: regulatory relationships inference에서 능력 확인. 핵심: scYeast biological-knowledge-guided foundation model로 yeast systems biology 적용 확산 — model organism 영역 확장. **8월 19일 Diversifying Day vs 오늘의 차별점**: 8/19가 **Wang CellVQ**으로 **68M cells + 500M parameters + SCD interpretability**를, **Pedrocchi bioRxiv**으로 **SAEs로 scFM 내부 메커니즘 통제**를, **Yiu Journal Translational Medicine**으로 **comprehensive review**를 제시했다면, 오늘은 **Kendiukhov Computational Biology Chemistry**으로 **foundation model perturbation adversarial validation framework 확립**을(검증 체계), **Abir NAR Genomics Bioinformatics**으로 **CFM-GP conditional flow matching으로 gene perturbation prediction 확산**을(예측 정확도), **Fan Synthetic Systems Biotechnology**으로 **scYeast biological-knowledge-guided model로 yeast 영역 확산**을(모델 organisms 확산) 동시에 제시한다. Diversifying(8/19) → foundation model跨영역 검증·예측·적용 확산 Expanding(8/20). 실무 함의: 단일세포 연구팀에서 Kendiukhov et al.의 adversarial validation framework를 분석하여 foundation model 적용 신뢰성 전략을 수립해야 한다. *출처: [Kendiukhov Foundation Model Adversarial Validation Computational Biology Chemistry 2026](https://consensus.app/papers/details/10.1016/j.compbiolchem.2026.109079/), [Abir CFM-GP Conditional Flow Matching NAR Genomics Bioinformatics 2026](https://consensus.app/papers/details/10.1093/nargab/lqag087/), [Fan scYeast Synthetic Systems Biotechnology 2026](https://consensus.app/papers/details/10.1016/j.synbio.2026.05.014/)* *#SingleCell #FoundationModel #Kendiukhov #Geneformer #AdversarialValidation #ComputationalBiology #Abir #CFMGP #ConditionalFlowMatching #NARGenoBioinformatics #Fan #scYeast #SyntheticSystemsBiotechnology #Yeast #BiologicalPriors #ExpandingDay #CrossDomain #Interpretability #PerturbationPrediction #CellType #TransferLearning #ZeroShot #RegulatoryNetworks* --- ### Post 6: FDA/규제 — CAPItello-281 FDA Approval과 ALS Three Converging Therapeutic Approaches 확산 📋 **[FDA/규제] CAPItello-281 FDA 승인으로 PTEN-deficient prostate cancer biomarker-guided targeted therapy paradigm 확립(Staton Cancer Biology Therapy 2026) + ALS 치료 where iPSC drug discovery·cell therapy·gene therapy three converging approaches 구체화(Morimoto Regenerative Therapy 2026) + BMP-7 mRNA delivered by fibrin-CaP scaffolds의 osteogenic programs 활성화 확인(Del Toro Runzer Bioactive Materials 2026): FDA/규제 영역의跨영역 적용 확산 동시 확인** FDA/규제의**跨영역 적용 확산**이 출처에서 동시에 확인된다[13][14][15]. **CAPItello-281: PTEN-Deficient Prostate Cancer Biomarker-Guided FDA Approval[13]** Allison Staton et al.(Cancer Biology & Therapy 2026)의 review는 CAPItello-281 trial의 FDA 승인을 분석한다. **PTEN deficiency**: advanced prostate cancer의 aggressive subgroup으로 poor clinical outcomes와 limited targeted therapeutic options 관련. **Capivasertib**: selective oral AKT inhibitor로 PI3K/AKT pathway downstream signaling 억제. **CAPItello-281(NCT04493853) 결과**: abiraterone acetate + androgen deprivation therapy(ADT)에 capivasertib 추가 시 radiographic progression-free survival 유의미 개선. **FDA approval**: PTEN-deficient mCSPC(metastatic castration-sensitive prostate cancer) 치료제 승인. **Notably adverse events**: hyperglycemia, diarrhea, rash. **Implication**: biomarker-guided therapy paradigm 확립 — PTEN deficiency가 치료 표적으로 확립. 핵심: CAPItello-281 FDA 승인으로 biomarker-guided targeted therapy paradigm 확립 — molecular biomarker 기반 규제 패러다임 확산. **ALS Three Converging Therapeutic Approaches: 2020-2026 구체화[14]** Satoru Morimoto et al.(Regenerative Therapy 2026)의 review는 2020-2026년 사이 ALS 치료 패러다임의 convergent evolution을 분석한다. **Tofersen(Qalsody) FDA accelerated approval(2023)**: SOD1 mutation-targeted ALS 최초 치료제. **iPSC-based drug discovery**: ropinirole과 bosutinib이 Japanese institutions 주도 Phase trials 완료. **Cell therapy**: regulatory T cells targeting neuroinflammation — efficacy 미확정. **Next-generation gene-silencing**: RNAi therapeutics + AAV-delivered microRNA가 2024-2025년 first-in-human trials 진입. **STMN2 discovery**: TDP-43 downstream target로 sporadic ALS(전체의 약 90%) 치료 표적 제시. **ANQUR trial(QRL-201)**: STMN2 target engagement interim data 보고. 핵심: ALS에서 iPSC drug discovery·cell therapy·gene therapy three converging approaches 구체화 — 신경퇴행성 질환 치료 확산. **BMP-7 mRNA Fibrin-CaP Scaffolds: osteogenic Programs 활성화[15]** Claudia Del Toro Runzer et al.(Bioactive Materials 2026)의 연구는 BMP-7 chemically modified mRNA(cmRNA)의 골 재생 가능성을 분석한다. **FDA-approved BMPs 한계**: BMP-2와 BMP-7의 supraphysiological doses 필요, high costs, adverse side effects. **BMP-7 cmRNA delivered by fibrin-calcium phosphate scaffold**: 최적화된 lipid vectors 사용. **In vivo osteogenesis**: 호흡기/osmic ossification 확인, highest dose가 largest ectopic bony growth 유도. **동반 효과**: angiogenesis와 neurogenesis 동시 관찰 — coordinated tissue regeneration. **적용 가능성**: 다른 조직으로 확장 가능. 핵심: BMP-7 mRNA scaffold로 osteogenic programs 활성화 — mRNA therapeutics의 골 재생 영역 확산. **8월 19일 Diversifying Day vs 오늘의 차별점**: 8/19가 **Jian Cancer Letters**으로 **2024년 13개 CGT 4기관 비교 분석 체계**를, **Huang Clinical Pharmacology**으로 **China NMPA CGTPs 승인 도전 과제**를, **Hwang Cytotherapy**으로 **Asia-Pacific CGT 규제 mature화**를 제시했다면, 오늘은 **Staton Cancer Biology Therapy**으로 **CAPItello-281 biomarker-guided FDA approval**을(molecular biomarker 규제 확산), **Morimoto Regenerative Therapy**으로 **ALS three converging approaches 구체화**를(신경퇴행성 질환 적용 확산), **Del Toro Runzer Bioactive Materials**으로 **BMP-7 mRNA 골 재생 적용**을(mRNA therapeutics 영역 확산) 동시에 제시한다. Diversifying(8/19) → 규제 biomarker 적용 확산 Expanding(8/20). 실무 함의: 규제 기획팀에서 Morimoto et al.의 ALS three converging approaches 분석을 참조하여신경퇴행성 질환 pipeline strategy를 수립해야 한다. *출처: [Staton CAPItello-281 Cancer Biology Therapy 2026](https://consensus.app/papers/details/10.1080/15384047.2026.2694128/), [Morimoto ALS Regenerative Therapy 2026](https://consensus.app/papers/details/10.1016/j.reth.2026.101150/), [Del Toro Runzer BMP-7 mRNA Bioactive Materials 2026](https://consensus.app/papers/details/10.1016/j.bioactmat.2026.05.046/)* *#FDA #CAPItello281 #Staton #CancerBiologyTherapy #PTEN #ProstateCancer #AKTInhibitor #Capivasertib #Morimoto #RegenerativeTherapy #ALS #iPSC #CellTherapy #GeneTherapy #Tofersen #STMN2 #Qalsody #DelToroRunzer #BioactiveMaterials #BMP7 #mRNA #Osteogenesis #Angiogenesis #Neurogenesis #ExpandingDay #BiomarkerGuided #Regulatory #TargetedTherapy #Neurodegenerative #TDP43 #RNAi #AAV* --- ### Post 7: Spatial Transcriptomics — CAF-T Cell Adenosine Axis과 CD3+ B Cells Microenvironment Remodeling 확산 🗺️ **[Spatial Transcriptomics] CAF-T cell purinergic adenosine signaling axis으로 NSCLC 예후 예측 biomarker 확립(Koppensteiner Oncoimmunology 2026) + CD3+ B cells이 DLBCL tumor microenvironment를 재구성하여 immunotherapy resistance mechanism 확산(Lang Cancer Biology Therapy 2026) + Bacterial LPS-immune cell crosstalk가 colorectal cancer microenvironment调节으로 확산(Walberg Gut Microbes 2026): spatial transcriptomics의跨영역 적용 확산 동시 확인** Spatial Transcriptomics의**跨영역 적용 확산**이 출처에서 동시에 확인된다[16][17][18]. **CAF-T Cell Adenosine Axis: NSCLC 예후 예측 Biomarker 확립[16]** Lilian Koppensteiner et al.(Oncoimmunology 2026)의 연구는 cancer-associated fibroblasts(CAFs)와 T cell의 purinergic crosstalk를 분석한다. **CD39과 CD73의 역할**: extracellular ATP를 adenosine로 전환하여 tumor immune evasion 촉진. **NSCLC 적용**: CD4+와 CD8+ T cells의 CD39/CD73 expression이 CAF co-culture에서 상향조절. **AMP와 adenosine 합성**: 기능적 수준의 production 확인. **TCGA 데이터**: adenosine signaling이 lung squamous cell carcinoma에서 poor outcome 예측. **GeoMx spatial transcriptomics**: high adenosine signature vs low adenosine signature tumor stroma의 transcriptomics 차이 분석. 핵심: CAF-T cell adenosine axis로 NSCLC 예후 예측 biomarker 확립 — spatial immunology의跨영역 적용. **CD3+ B Cells: DLBCL Tumor Microenvironment Remodeling[17]** Mingxiao Lang et al.(Cancer Biology & Therapy 2026)의 연구는 DLBCL에서 CD3+ B cells의 tumor microenvironment 재구성 mechanism을 분석한다. **예상치 못한 발견**: malignant B cells의 subset이 T cell marker인 CD3를 express. **Five key regulatory genes**: BCLAF1, CHURC1, FLI1, NFATC2, ELF2로 specific genetic circuit 구성. **Macrophage enrichment와 M2 polarization**: TGF-β signaling 관련. **Immunosuppressive tumor microenvironment 재구성**: advanced disease stage, poor treatment response, reduced survival과 상관관계. **Spatial과 functional analyses**: multi-omics integration으로 검증. 핵심: CD3+ B cells로 DLBCL microenvironment 재구성 확인 — immunotherapy resistance mechanism의跨영역 적용. **Bacterial LPS-Immune Cell Crosstalk: CRC Microenvironment Modulation[18]** Åsa Walberg et al.(Gut Microbes 2026)의 연구는 colorectal cancer에서 bacterial lipopolysaccharide(LPS)와 immune cells의 crosstalk를 분석한다. **방법**: 3D light-sheet imaging, spatial transcriptomics, imaging mass cytometry 조합. **CRC-adjacent tissue**: CD11c dendritic cells, CD15 neutrophils, CD163 macrophages와 bacterial LPS colocalization. **CRC tissue 변화**: CD163 macrophages와 CD11c dendritic cells의 LPS colocalization 감소, CD15 neutrophils 증가. **Immune cell composition 차이**: tumor vs adjacent tissue에서 현저한 차이. **3D spatial distribution**: bacteria와 immune cells의 공간적 상호작용 이해深化. 핵심: Bacterial LPS-immune cell crosstalk로 CRC microenvironment modulation 확인 — spatial microbiology의跨영역 적용. **8월 19일 Diversifying Day vs 오늘의 차별점**: 8/19가 **Siaw Journal Pathology**으로 **neuroblastoma FFPE에서 CCL18/PITPNM3 신호 축**을, **Ren Nature Communications**으로 **Stereo-seq·Visium HD·CosMx·Xenium 4개 플랫폼 ground truth benchmark**를, **Wang Nature Communications**으로 **imaging ST Xenium vs MERSCOPE vs CosMx sensitivity 차이**를 제시했다면, 오늘은 **Koppensteiner Oncoimmunology**으로 **CAF-T cell adenosine axis로 NSCLC 예후 biomarker**을(새 biology mechanism), **Lang Cancer Biology Therapy**으로 **CD3+ B cells의 DLBCL microenvironment 재구성**을(immune-cell biology), **Walberg Gut Microbes**으로 **bacterial LPS-CRC immune crosstalk**을(microbiome 영역) 동시에 제시한다. Diversifying(8/19) → spatial transcriptomics跨영역 biology mechanism 확산 Expanding(8/20). 실무 함의: spatial transcriptomics 연구팀에서 Koppensteiner et al.의 adenosine axis 분석을 참조하여 tumor microenvironment targeting strategy를 수립해야 한다. *출처: [Koppensteiner CAF T Cell NSCLC Oncoimmunology 2026](https://consensus.app/papers/details/10.1080/2162402X.2026.2709221/), [Lang CD3+ B Cells DLBCL Cancer Biology Therapy 2026](https://consensus.app/papers/details/10.1080/15384047.2026.2684140/), [Walberg Bacterial LPS CRC Gut Microbes 2026](https://consensus.app/papers/details/10.1080/19490976.2026.2665878/)* *#SpatialTranscriptomics #Koppensteiner #Oncoimmunology #NSCLC #CAFs #Adenosine #CD39 #CD73 #CD3 #Lang #CancerBiologyTherapy #DLBCL #TumorMicroenvironment #CD3Positive #Walberg #GutMicrobes #CRC #ColorectalCancer #LPS #Bacteria #ImmuneCrosstalk #ExpandingDay #CrossDomain #SpatialOmics #TILs #Macrophages #ImmuneEvasion #Biomarker #Microbiome #TME* --- ### Post 8: 오늘의 요약 — Expanding(확산 Day) 핵심 정리 🧬 **오늘 6개 영역 핵심 요약:** 8/20(Expanding)의 핵심: Diversifying(8/19)된 기술들이 **跨영역(cross-domain)으로 확산(Expanding)하여 새 적용 영역의 조건을 충족하는 날**이었다. **1. ISS Spatial Profiling Gene Editing 확산(Janjuha Nature Biomedical Engineering 2025)**: In situ sequencing으로 gene editing events를 공간적 분해능으로 매핑 — mice·macaques·종양/대사성 질환으로 확산. [Janjuha Nature Biomedical Engineering 2025] **2. mRNA/LNP Vaccine De-targeting Framework(Froechlich Molecular Therapy 2026)**: De-targeting elements로 tissue-specific antigen silencing + Cas9 de-immunization 동시 달성 — vaccine optimization에서 gene therapy로 확산. [Froechlich Molecular Therapy 2026] **3. RNA-LNP PE7 CTLN1 치료 가능성(Tálas Science Translational Medicine 2026)**: AAV 71%/RNA-LNP 24% 교정율 + 완전한 생존률 회복 — 대사성 유전 질환 적용. [Tálas Science Translational Medicine 2026] **4. DrugCLIP Contrastive Learning Genome-Wide Screening(Zhang Drug Development Research 2026)**: Contrastive learning으로 ultrafast genome-wide virtual screening 가능 — AI drug discovery의適用방식 확산. [Zhang Drug Development Research 2026] **5. CAF-T Cell Adenosine Axis NSCLC 예후 Biomarker(Koppensteiner Oncoimmunology 2026)**: CD39/CD73-mediated adenosine로 lung squamous cell carcinoma poor outcome 예측 — spatial immunology biomarker 확립. [Koppensteiner Oncoimmunology 2026] **6. CAPItello-281 Biomarker-Guided FDA Approval(Staton Cancer Biology Therapy 2026)**: PTEN-deficient prostate cancer에서 capivasertib FDA 승인 — molecular biomarker 기반 규제 패러다임 확산. [Staton Cancer Biology Therapy 2026] **8월 21일 전망**: Expanding된 기술들의跨영역 적용 속도와 새 영역采纳가 핵심 변수. 특히 ISS spatial profiling의 임상 샘플 적용, DrugCLIP의 drug discovery pipeline 통합, CAPItello-281 biomarker-guided paradigm의 다른 종양 적용이 관전. *출처: [Janjuha ISS Nature Biomedical Engineering 2025](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/), [Froechlich mRNA LNP Molecular Therapy 2026](https://consensus.app/papers/details/10.1016/j.ymthe.2026.07.050/), [Tálas CTLN1 Science Translational Medicine 2026](https://consensus.app/papers/details/10.1126/scitranslmed.aec7274/), [Zhang DrugCLIP Drug Development Research 2026](https://consensus.app/papers/details/10.1002/ddr.70351/), [Raghupathi Big Data Healthcare Health Information Science Systems 2026](https://consensus.app/papers/details/10.1007/s13755-026-00433-2/), [de Oliveira Teixeira AlphaFold AMR Journal Computer-Aided Molecular Design 2026](https://consensus.app/papers/details/10.1007/s10822-026-00905-3/), [Tortolani GPR18 Biochemical Pharmacology 2026](https://consensus.app/papers/details/10.1016/j.bcp.2026.118038/), [Dhir AI Drug Design RSC Advances 2026](https://consensus.app/papers/details/10.1039/d6ra02374f/), [Kendiukhov Adversarial Validation Computational Biology Chemistry 2026](https://consensus.app/papers/details/10.1016/j.compbiolchem.2026.109079/), [Abir CFM-GP NAR Genomics Bioinformatics 2026](https://consensus.app/papers/details/10.1093/nargab/lqag087/), [Fan scYeast Synthetic Systems Biotechnology 2026](https://consensus.app/papers/details/10.1016/j.synbio.2026.05.014/), [Staton CAPItello-281 Cancer Biology Therapy 2026](https://consensus.app/papers/details/10.1080/15384047.2026.2694128/), [Morimoto ALS Regenerative Therapy 2026](https://consensus.app/papers/details/10.1016/j.reth.2026.101150/), [Del Toro Runzer BMP-7 Bioactive Materials 2026](https://consensus.app/papers/details/10.1016/j.bioactmat.2026.05.046/), [Koppensteiner CAF NSCLC Oncoimmunology 2026](https://consensus.app/papers/details/10.1080/2162402X.2026.2709221/), [Lang CD3+ DLBCL Cancer Biology Therapy 2026](https://consensus.app/papers/details/10.1080/15384047.2026.2684140/), [Walberg LPS CRC Gut Microbes 2026](https://consensus.app/papers/details/10.1080/19490976.2026.2665878/)* *#ExpandingDay #Summary #Janjuha #ISS #SpatialProfiling #Froechlich #DeTargeting #Tálas #CTLN1 #PrimeEditing #Zhang #DrugCLIP #ContrastiveLearning #Raghupathi #BigData #Healthcare #deOliveiraTeixeira #AlphaFold #AMR #Tortolani #GPR18 #Neuroinflammation #Dhir #AIDrugDesign #Kendiukhov #AdversarialValidation #Abir #CFMGP #FlowMatching #Fan #scYeast #Staton #CAPItello281 #PTEN #Morimoto #ALS #Tofersen #DelToroRunzer #BMP7 #mRNA #Osteogenesis #Koppensteiner #CAFs #Adenosine #Lang #CD3B #DLBCL #Walberg #LPS #CRC #Expanding #Diversifying #CrossDomain #SpatialGenomics #SpatialOmics #Biomarker #Regulatory #Immunotherapy* --- ## Sources [1] [Janjuha et al. — Spatial profiling of gene editing by in situ sequencing in mice and macaques. Nature Biomedical Engineering 2025](https://consensus.app/papers/details/ab669ea6603759258fd73951324f50a5/) [2] [Froechlich et al. — Tissue-specific silencing of synthetic mRNAs by de-targeting elements maps vaccination-competent tissues and allows Cas9 de-immunization. Molecular Therapy 2026](https://consensus.app/papers/details/10.1016/j.ymthe.2026.07.050/) [3] [Tálas et al. — RNA-LNP-mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type I. Science Translational Medicine 2026](https://consensus.app/papers/details/10.1126/scitranslmed.aec7274/) [4] [Zhang — Contrastive Learning-Powered Ultrafast Genome-Wide Virtual Screening: The Rise of DrugCLIP. Drug Development Research 2026](https://consensus.app/papers/details/10.1002/ddr.70351/) [5] [Raghupathi & Raghupathi — Big data in healthcare and medicine revisited design and managerial challenges in the age of artificial intelligence. Health Information Science and Systems 2026](https://consensus.app/papers/details/10.1007/s13755-026-00433-2/) [6] [de Oliveira Teixeira et al. — Innovative approaches to therapeutic target discovery amid the global challenge of antimicrobial resistance. Journal of Computer-Aided Molecular Design 2026](https://consensus.app/papers/details/10.1007/s10822-026-00905-3/) [7] [Tortolani et al. — Targeting GPR18: Structural modelling, ligand discovery, and therapeutic potential in neuroinflammatory disorders. Biochemical Pharmacology 2026](https://consensus.app/papers/details/10.1016/j.bcp.2026.118038/) [8] [Dhir et al. — AI-driven computational drug design: tools, workflow and challenges. RSC Advances 2026](https://consensus.app/papers/details/10.1039/d6ra02374f/) [10] [Kendiukhov — Adversarial validation of in silico perturbation profiles for intelligence-associated genes in human prefrontal cortex. Computational Biology and Chemistry 2026](https://consensus.app/papers/details/10.1016/j.compbiolchem.2026.109079/) [11] [Abir et al. — CFM-GP: unified conditional flow matching to learn gene perturbation across cell types. NAR Genomics and Bioinformatics 2026](https://consensus.app/papers/details/10.1093/nargab/lqag087/) [12] [Fan et al. — scYeast: a biological-knowledge-guided foundation model on yeast single-cell transcriptomics. Synthetic Systems Biotechnology 2026](https://consensus.app/papers/details/10.1016/j.synbio.2026.05.014/) [13] [Staton et al. — Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy. Cancer Biology & Therapy 2026](https://consensus.app/papers/details/10.1080/15384047.2026.2694128/) [14] [Morimoto et al. — Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy-Advances through 2026. Regenerative Therapy 2026](https://consensus.app/papers/details/10.1016/j.reth.2026.101150/) [15] [Del Toro Runzer et al. — BMP-7 mRNA delivered by Fibrin-CaP scaffolds activates osteogenic programs in vivo. Bioactive Materials 2026](https://consensus.app/papers/details/10.1016/j.bioactmat.2026.05.046/) [16] [Koppensteiner et al. — Cancer associated fibroblast-T cell crosstalk promotes purinergic synthesis in non-small cell lung cancer (NSCLC). Oncoimmunology 2026](https://consensus.app/papers/details/10.1080/2162402X.2026.2709221/) [17] [Lang et al. — Neoplastic CD3+ B cells remodel the DLBCL tumor microenvironment via single-cell and spatial transcriptomics. Cancer Biology & Therapy 2026](https://consensus.app/papers/details/10.1080/15384047.2026.2684140/) [18] [Walberg et al. — Altered crosstalk of bacterial lipopolysaccharide with immune cells in colorectal cancer compared to paired adjacent intestinal tissue. Gut Microbes 2026](https://consensus.app/papers/details/10.1080/19490976.2026.2665878/)
Research Pulse·2026-08-20
Research Pulse — 2026-08-20
28 journals × 7 topics · fibrosis · OXPHOS · ferroptosis · sarcopenia · senescence
Raw data + scoring: Daily Tech Digest (separate feed)
Request a Paid Brief